The latin American dili registry experience: A successful ongoing collaborative strategic initiative

International Journal of Molecular Sciences

Volumn 17, Issue 3, 2016, Pages

  Bessone, Fernando ^a   Hernandez, Nelia ^b   Lucena, M Isabel ^c   Andrade, Raúl J ^c  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b HOSPITAL DE CLÍNICAS   (Uruguay)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Drug induced liver injury; Hepatotoxicity; Herbals and dietary supplements; Latin American DILI registry; Registry; Spanish DILI registry

Indexed keywords

BIOLOGICAL MARKER;

DISEASE COURSE; DISEASE REGISTRY; DISEASE SEVERITY; HUMAN; INFORMATION PROCESSING; LIVER TOXICITY; MORBIDITY; REVIEW; SOUTH AND CENTRAL AMERICA; TOXIC HEPATITIS; CHEMICAL AND DRUG INDUCED LIVER INJURY; ETHNOLOGY; INTERNATIONAL COOPERATION; REGISTER; SOUTH AMERICA; SPAIN;

CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS; INTERNATIONAL COOPERATION; REGISTRIES; SOUTH AMERICA; SPAIN;

EID: 84959321814     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17030313     Document Type: Review

References (39)

1. Andrade, R.J.; Lucena, M.I.; Fernández, M.C.; Pelaez, G.; Pachkoria, K.; García Ruiz, E.; García-Muñoz, B.; González-Grande, R.; Pizarro, A.; Durán, J.A.; et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10 year period. Gastroenterology 2005, 129, 512-521. [CrossRef] [PubMed]
2. Björnsson, E.S.; Bergmann, O.M.; Björnsson, H.K.; Kvaran, R.B.; Olafsson, S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144, 1419-1425. [CrossRef] [PubMed]
3. Takikawa, H.; Murata, Y.; Horiike, N.; Fukui, H.; Onji, M. Drug-induced liver injury in Japan: An analysis of 1676 cases between 1997 and 2006. Hepatol. Res. 2009, 39, 427-431. [CrossRef] [PubMed]
4. Chalasani, N.; Bonkovsky, H.L.; Fontana, R.; Lee, W.; Stolz, A.; Talwalkar, J.; Reddy, K.R.; Watkins, P.B.; Navarro, V.; Barnhart, H.; et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015, 148, 1340-1352. [CrossRef] [PubMed]
5. Hernandez, N.; Bessone, F.; Sanchez, A.; di Pace, M.; Brahm, J.; Zapata, R.A.; Chirino, R.; Dávalos, M.; Méndez-Sánchez, N.; Arrese, M.; et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann. Hepatol. 2014, 13, 231-238. [PubMed]
6. Leyva-Flores, R.; Erviti-Erice, J.; Kageyama-Escobar, M.L.; Arredondo, A. Medical prescription, drug Access and drug expenditure among health service users in Mexico. Salud Publ. Mex 1998, 40, 24-31.
7. Bénard-Laribière, A.; Miremont-Salamé, G.; Pérault-Pochat, M.C.; Noize, P.; Haramburu, F. Incidence of hospital admissions due to adverse drug reactions in France: The EMIR study. Fundam. Clin. Pharmacol. 2015, 29, 106-111. [CrossRef] [PubMed]
8. Lazarou, J.; Pomeranz, B.H.; Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998, 279, 1200-1205. [CrossRef] [PubMed]
9. Bégaud, B.; Martin, K.; Haramburu, F.; Moore, N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002, 288, 1588. [CrossRef] [PubMed]
10. Björnsson, E.S.; Hoffnagle, J.H. Categorization of drug implicated in causing liver injury: Critical assessment based upon case reports. Hepatology 2016, 63, 590-603. [CrossRef] [PubMed]
11. Bessone, F.; Colombato, L.; Fassio, E.; Reggiardo, M.; Vorobioff, J.; Tanno, H. The spectrum of nimesulide induce hepatotoxicity. An overview. Antiinflamm. Antiallergy Agents Med. Chem. 2010, 9, 355-365. [CrossRef]
12. Bessone, F.; Colombato, L.; Frider, B.; Tsariktsian, G.; Bruguera, M.; Cohen, H.; Tsariktsian, G.; Hernández, N.; Bruguera, M.; Gualano, G.; et al. Cyproterone induced-liver-injury includes autoimmune hepatitis and a spectrum of varying severity of acute hepatcellular damage. Basic Clin. Pharmacol. Toxicol. 2011, 109, 32-40.
13. Suzuki, A.; Andrade, R.J.; Bjornsson, E.; Lucena, M.I.; Lee,W.M.; Yuen NA Hunt, C.M.; Freston, J.W. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase. Drug Saf. 2010, 33, 503-522. [CrossRef] [PubMed]
14. Zapata, R.; Sanhueza, E.; Gómez, F.; Contreras, J.; Uribe, M.; Humeres, R.; Martínez, A.; Rius, M.; Basaez, A.M.; Rios, H.; et al. Falla hepática fulminante en adultos. Etiología, pronóstico y evolución de pacientes evaluados en dos unidades de trasplante hepático en Chile durante una década. Gastroenterol. Latinoam. 2012, 23, S40.
15. Medicines Control Agency, Department of Health. Consultation Letter MLX231. Analgesic Medicines Available Without Prescription: Proposed Changes to Product Information and Sale or Supply of Paracetamol; Department of Health: London, UK, 1996.
16. Hawkins, L.C.; Edwards, J.N.; Dargan, P.I. Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom. Drug Saf. 2007, 30, 465-479. [CrossRef] [PubMed]
17. Limiting Acetaminophen's Strength in Prescription Medicines. All manufacturers of prescription combination drug products with more than 325 mg of acetaminophen have discontinued marketing. Available online: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm165107.htm (accessed on 20 September 2015).
18. Teschke, R.;Wolff,W.; Frenzel, C.; Schulze, J.; Eickhoff, A. Herbal hepatotoxicity: A tabular compilation of reported cases. Liver Int. 2012, 32, 1543-1556. [CrossRef] [PubMed]
19. Teschke, R.; Zhang, L.; Long, H.; Schwarzenboeck, A.; Schmidt-Taenzer, W.; Genthner, A.; Wolff, A.; Frenzel, C.; Schulze, J.; Eickhoff, A. Traditional Chinese medicine and herbal hepatotoxicity: A tabular compilation of reported cases. Ann. Hepatol. 2015, 14, 7-19. [PubMed]
20. Zhou, Y.; Yang, L.; Liao, Z.; He, X.; Zhou, Y.; Guo, H. Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21,789 patients. Eur. J. Gastroenterol. Hepatol. 2013, 25, 825-829. [CrossRef] [PubMed]
21. García-Cortés, M.; Borraz, Y.; Lucena, M.I.; Peláez, G.; Salmerón, J.; Diago, M.; Martínez-Sierra, M.C.; Navarro, J.M.; Planas, R.; Soria, M.J.; et al. Liver injury induced by "natural remedies": An analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev. Esp. Enferm. Dig. 2008, 11, 688-695.
22. Lucena, M.I.; Cohen, H.; Hernandez, N.; Bessone, F.; Dacoll, C.; Stephens, C.; Borraz, Y.; Ulzurrun, E.; Bruguera, M.; Andrade, J.R. Hepatotoxicidad, un problema real con especificidades locales: Hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad. Gastroenterol. Hepatol. 2011, 34, 361-368. [CrossRef]
23. Bessone, F.; Hernandez, N.; Davalos, M.; Parana, R.; Schinoni, M.; Lizarzabal, M.; Kershenobich, D.; Loaeza, A.; Arrese, M.; Chirino, R.A.; et al. Building a spanish Latin American network on drug induced liver injury: Much to get from a joint collaborative initiative. Ann. Hepatol. 2012, 11, 544-549. [PubMed]
24. Asociación Latinoamericana para el estudio del Hígado. Available online: http://www.alehlatam.org (accessed on 20 September 2015).
25. Jacobsen, K.H.; Wiersma, S.T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccination 2010, 28, 6653-6657. [CrossRef] [PubMed]
26. Echevarría, J.M.; González, J.E.; Lewis-Ximenez, L.L.; Dos Santos, D.R.; Munné, M.S.; Pinto, M.A.; Pujol, F.H.; Rodríguez-Lay, L.A. Hepatitis E virus infection in Latin America: A review. J. Med. Virol. 2013, 85, 1037-1045. [CrossRef] [PubMed]
27. Cruells, M.R.; Mescia, G.; Gaibisso, R.; Ramírez, M.; Gutiérrez, M.; Kohen, S.; González, M.; Russi, J.; Chiparelli, H.; Ucar, L.; et al. Epidemiological study of hepatitis A and E viruses in different populations in Uruguay. Gastroenterol. Hepatol. 1997, 20, 295-298. [PubMed]
28. Mendizabal, M.; Marciano, S.; Videla, M.G.; Anders, M.; Zerega, A.; Balderramo, D.C.; Chan, D.; Barrabino, M.; Gil, O.; Mastai, R.; et al. Changing etiologies and outcomes of acute liver failure: Perspectives from 6 transplant centers in Argentina. Liver Transpl. 2014, 20, 483-489. [CrossRef] [PubMed]
29. Danan, G.; Benichou, C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 1993, 46, 1323-1330. [CrossRef]
30. Bessone, F.; Lucena, M.I.; Roma, M.; Stephens, C.; Medina-Cáliz, I.; Frider, B.; Tsariktsian, G.; Hernández, N.; Bruguera, M.; Gualano, G.; et al. Cyproterone acetate induces a wide spectrum of liver damage including corticosteroid-responsive hepatitis: Report of 22 cases. Liver Int. 2016, 36, 302-310. [CrossRef] [PubMed]
31. Robles-Diaz, M.; Gonzalez-Jimenez, A.; Medina-Caliz, I.; Stephens, C.; García-Cortes, M.; García-Muñoz, B.; Ortega-Alonso, A.; Blanco-Reina, E.; Gonzalez-Grande, R.; Jimenez-Perez, M.; et al. Distinct phenotype of Hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment. Pharmacol. Ther. 2015, 41, 116-125. [CrossRef] [PubMed]
32. Robles-Diaz, M.; Lucena, M.I.; Kaplowitz, N.; Stephens, C.; Medina-Cáliz, I.; González-Jimenez, A.; Ulzurrun, E.; Gonzalez, A.F.; Fernandez, M.C.; Romero-Gómez, M.; et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014, 147, 109-118. [CrossRef] [PubMed]
33. Bessone, F.; Hernández, N.; Sánchez, A.; di Pace, M.; Gualano, G.; Arrese, M.; Ruiz, A.; del Castillo, A.L.; Girala, M.A.; Carrera, E.; et al. A comparative analysis of the Spanish and Latin-American prospective drug-induced liver injury (DILI) networks. Hepatology 2015, 62, 504A.
34. Lucena, M.I.; Molokhia, M.; Shen, Y.; Urban, T.J.; Aithal, G.P.; Andrade, R.J.; Day, C.P.; Ruiz-Cabello, F.; Donaldson, P.T.; Stephens, C.; et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141, 338-347. [CrossRef] [PubMed]
35. Daly, A.K.; Donaldson, P.T.; Bhatnagar, P.; Shen, Y.; Pe'er, I.; Floratos, A.; Daly, M.J.; Goldstein, D.B.; John, S.; Nelson, M.R.; et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41, 816-819. [CrossRef] [PubMed]
36. Singer, J.B.; Lewitzky, S.; Leroy, E.; Yang, F.; Zhao, X.; Klickstein, L.;Wright, T.M.; Meyer, J.; Paulding, C.A. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 2010, 42, 711-714. [CrossRef] [PubMed]
37. Spraggs, C.F.; Budde, L.R.; Briley, L.P.; Bing, N.; Cox, C.J.; King, K.S.; Whittaker, J.C.; Mooser, V.E.; Preston, A.J.; Stein, S.H.; et al. HLA-DQA1*02:01 is a major risk factor for lapatanib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 2011, 29, 667-673. [CrossRef] [PubMed]
38. Slim, M.; Stephens, C.; Robles-Diaz, M.; Medina-Caliz, I.; Ortega-Alonso, A.; Lucena, M.I.; Aithal, G.P.; Andrade, R.J. Pro-Euro-DILI Registry: A collaborative effort to enhance the understanding of DILI. J. Hepatol. submitted for publication. 2016.
39. Aithal, G.P.; Grove, J.; Bjornsson, E.; Lucena, M.I.; Andrade, R.J.; Hallberg, P.; Stephens, C.; Par, H.; Maitland-van der Zee, A.H.; Martin, J.H.; et al. HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds. Hepatology 2015, 62, 325A-326A.